Enliven Therapeutics, Inc. (ELVN)
NASDAQ:ELVN
Want to see ELVN full AI Analyst Report?
ELVN Stock Chart & Stats
$48.11
$0.01(0.04%)
At close: 4:00 PM EST
$48.11
$0.01(0.04%)
Day’s Range― - ―
52-Week Range$14.79 - $48.53
Previous CloseN/A
Volume37.78K
Average Volume (3M)751.24K
Market Cap
$2.46B
Enterprise Value$2.28B
Total Cash (Recent Filing)$452.40M
Total Debt (Recent Filing)$302.00K
Price to Earnings (P/E)―
Beta1.01
Next Earnings
Aug 19, 2026EPS Estimate
-0.4Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.64
Shares Outstanding60,904,945
10 Day Avg. Volume964,264
30 Day Avg. Volume751,243
Financial Highlights & Ratios
PEG Ratio2.65
Price to Book (P/B)1.90
Price to Sales (P/S)0.00
P/FCF Ratio-12.38
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-37.97K
Enterprise Value/Ebitda-23.11
Forecast
1Y Price Target
$59.63Price Target Upside23.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-1.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet, Minimal DebtNear-zero financial leverage and a materially larger equity base provide durable funding capacity for multi-year clinical development. This reduces short-term refinancing risk, supports sustained R&D spend for pivotal trials, and improves strategic optionality for partnerships or licensing.
Regulatory Alignment On Pivotal DoseClear FDA agreement on a Phase 3 dose and trial population materially reduces late‑stage design and regulatory uncertainty. That alignment improves predictability of endpoints and timelines, strengthening the probability of successful pivotal readouts and partner interest over the next 2–6 months and beyond.
Positive Phase 1 Efficacy And TolerabilityRobust efficacy (notably higher MMR at the chosen 80 mg dose) combined with a favorable safety profile and high ABL1 selectivity suggests a durable clinical advantage versus older TKIs. This supports a stronger clinical positioning, higher commercial potential, and better partnering/licensing prospects long term.
Bears Say
Pre-revenue With Sustained Cash BurnOngoing negative operating cash flows and roughly -$65M TTM free cash flow create a structural funding requirement. The company must rely on external capital until commercialization or partnership revenue, increasing refinancing exposure and the likelihood of future dilution.
Widening Operating LossesMaterially deeper operating losses over recent years mean negative returns on equity and limited internal capacity to invest beyond core programs. Without near-term revenue, sustained losses constrain strategic flexibility and elevate financial risk for multi-year development plans.
Dilution Risk From Expanded Shares And OfferingsDoubling authorized shares and active large common offerings structurally increases the chance of equity issuance to fund trials. While it improves financing flexibility, it also raises the probability of dilution, which can impair long-term per-share economics for existing investors.
Enliven Therapeutics News
ELVN FAQ
What was Enliven Therapeutics, Inc.’s price range in the past 12 months?
Enliven Therapeutics, Inc. lowest stock price was $14.79 and its highest was $48.53 in the past 12 months.
What is Enliven Therapeutics, Inc.’s market cap?
Enliven Therapeutics, Inc.’s market cap is $2.46B.
When is Enliven Therapeutics, Inc.’s upcoming earnings report date?
Enliven Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 68 days.
How were Enliven Therapeutics, Inc.’s earnings last quarter?
Enliven Therapeutics, Inc. released its earnings results on May 07, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.444 by $0.064.
Is Enliven Therapeutics, Inc. overvalued?
According to Wall Street analysts Enliven Therapeutics, Inc.’s price is currently Undervalued.
Does Enliven Therapeutics, Inc. pay dividends?
Enliven Therapeutics, Inc. does not currently pay dividends.
What is Enliven Therapeutics, Inc.’s EPS estimate?
Enliven Therapeutics, Inc.’s EPS estimate is -0.4.
How many shares outstanding does Enliven Therapeutics, Inc. have?
Enliven Therapeutics, Inc. has 60,904,945 shares outstanding.
What happened to Enliven Therapeutics, Inc.’s price movement after its last earnings report?
Enliven Therapeutics, Inc. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.444. Following the earnings report the stock price went up 1.142%.
Which hedge fund is a major shareholder of Enliven Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ELVN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Enliven Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$59.63 (23.93% Upside)
$59.63 (23.93% Upside)
Blogger Sentiment
Bullish
ELVN Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $295.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 2.8%
Last 30 Days ▼ 0.5%
Last 30 Days ▼ 0.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
70.50%
12-Months-Change
Fundamentals
Return on Equity
-21.04%
Trailing 12-Months
Asset Growth
53.63%
Trailing 12-Months
Company Description
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.
ELVN Stock 12 Month Forecast
Average Price Target
$59.63
▲(23.93% Upside)
Technical Analysis
Sarepta Therapeutics
―
Viridian Therapeutics
―
―
Intellia Therapeutics
―
AbCellera Biologics
―
Ownership Overview
16.37% Insiders
18.24% Mutual Funds
7.51% Other Institutional Investors
48.31% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---